AstraZeneca PLC
LSEAstraZeneca has clawed back 3.1% this week, but the recovery sits atop a 9.7% monthly decline — and the tension between a stabilising stock and a pipeline that keeps delivering trial wins defines where the name heads into July earnings. The borrow market tells a decidedly relaxed story. Short interest is negligible at just 0.17% of the free float, and it has been trending down…
Snapshot as of 22 Jun 2026
AstraZeneca has clawed back 3.1% this week, but the recovery sits atop a 9.7% monthly decline — and the tension between a stabilising stock and a pipeline that keeps delivering trial wins defines where the name heads…
AstraZeneca enters the first week of May carrying its heaviest monthly loss in years. The stock shed another 4.1% this week to close at 133.3p, dragging its one-month decline to almost 13%, as the sector wrestles with…
AstraZeneca heads into its Q1 2026 results — due before the London open on April 29 — after a choppy month that has left the stock nursing a 5% weekly loss and sitting near GBP 139. The lending market offers little…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for AZN — free to start on ORTEX.
Sign up for free →Open AZN on ORTEX